ULTRAGENYX PHARMACEUTICAL INC. Debt Securities, Available-for-sale, Amortized Cost
ULTRAGENYX PHARMACEUTICAL INC. (RARE) had Debt Securities, Available-for-sale, Amortized Cost of $372.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $372.00M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $455.00M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $665.00M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $368.26M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2026-06-30 | $372.00M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $455.00M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $665.00M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $368.26M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $478.99M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $509.28M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $695.00M 10-K · filed 2026-02-18 | $694.77M 10-K · filed 2025-02-19 |
| 2024-09-30 | $772.40M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $833.05M 10-Q · filed 2024-08-02 | |
| 2024-03-31 | $536.65M 10-Q · filed 2024-05-03 | |
| 2023-12-31 | $734.56M 10-K · filed 2025-02-19 | |
| 2023-09-30 | $497.40M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $596.10M 10-Q · filed 2023-08-04 | |
| 2023-03-31 | $693.25M 10-Q · filed 2023-05-05 | |
| 2022-12-31 | $882.36M 10-K · filed 2024-02-21 | |
| 2022-09-30 | $983.96M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $685.49M 10-Q · filed 2022-07-29 | |
| 2022-03-31 | $797.95M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $969.59M 10-K · filed 2023-02-17 | |
| 2020-12-31 | $1.17B 10-K · filed 2022-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |